文献速递药物相互作用抗栓抗凝管理特殊人群用药

癌症相关血栓管理中直接抗凝药与抗癌药的药代动力学药物相互作用

Pharmacokinetic drug-drug interactions with direct anticoagulants in the management of cancer-associated thrombosis.
PubMed 文献 · Br J Clin Pharmacol · 2023-05-23

本文综述癌症相关血栓治疗中直接口服抗凝药(DOACs)与抗癌药物之间的药代动力学药物相互作用(DDIs)。利伐沙班、艾多沙班和阿哌沙班在癌症相关血栓中不劣于低分子肝素,但出血事件增加。文章提供临床处理框架及实践建议。

要点

  • DOACs在癌症相关血栓中不劣于低分子肝素,但有出血增加信号。
  • 药代动力学DDIs是停用DOACs并换药的理由之一。
  • 临床实践中何为重要PK相互作用及如何处理,现有指导有限。

核心结论

  • 本文为临床医生处理DOACs与抗癌治疗间的药代动力学DDIs提供框架。
  • DOACs在癌症相关血栓中至少与低分子肝素同样有效,但出血事件增加。

研究设计与样本

  • 综述:讨论当前文献、PK特征与DDI标签信息的联系,并提供应用于临床病例的实践建议。

主要发现

  • 癌症相关血栓中,利伐沙班、艾多沙班和阿哌沙班不劣于低分子肝素,复发血栓事件有减少信号但出血事件增加。
  • 已识别出潜在重大药代动力学DDIs,作为不选用DOACs而选择替代方案的理由。

临床怎么用

  • 临床医生可借助本文框架处理DOACs与抗癌治疗间的药代动力学DDIs。

局限性

  • 关于何为重大药代动力学相互作用及临床实践中如何处理,实用指导有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug-drug interactions (DDIs) are common in cancer management and complicate the choice of anticoagulation in cancer-associated thrombosis. Cancer confers an increased risk of thrombotic events. Also, more bleeding events are observed in those who receive anticoagulation compared to those without cancer. In the treatment of cancer-associated thrombosis, direct oral anticoagulants (DOACs) have been found to be at least as effective as low-molecular weight heparins, which became the standard of care after several trials demonstrated superiority over vitamin K antagonists. Non-inferiority compared to low-molecular weight heparins has been shown for rivaroxaban, edoxaban and apixaban with a signal of fewer recurrent thrombotic events, albeit with an increase in bleeding events. Yet, potentially major pharmacokinetic drug-drug interactions have been identified as a reason to withhold DOACs and to rather choose an alternative. Practical guidance on what constitutes a major pharmacokinetic interaction and/or how to deal with these interactions in clinical practice is limited. Hence, here we have provided a framework to allow clinicians to better deal with pharmacokinetic drug-drug interactions between DOACs and cancer therapies in the management of cancer-associated thrombosis. In this review we have discussed the current literature, how the pharmacokinetic profile links to the label information on DDI, and have provided a practical proposal, applied to a clinical case.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Van der Linden L, Vanassche T, Van Cutsem E, et al. Pharmacokinetic drug-drug interactions with direct anticoagulants in the management of cancer-associated thrombosis. Br J Clin Pharmacol. 2023. PMID: 37170893. doi:10.1111/bcp.15785

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。